Physician profile
Retta Bright
NPI 1174928667
$1,966.94
in general payments reported to CMS, 2019-2025
18 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $546 · 2023: $521 · 2024: $155 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.72 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $690.42 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $236.34 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $220.65 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.54 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $163.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.97 | 2021-2023 | Trintellix |
| Corium, LLC | $59.37 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $58.89 | 2021-2022 | |
| Axsome Therapeutics, INC. | $51.57 | 2022-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $38.82 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $33.87 | 2022 | |
| Boston Scientific Corporation | $31.96 | 2025 | Lithocatch |
| Alkermes, INC. | $24.88 | 2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $18.70 | 2022 | |
| Owp Pharmaceuticals, INC. | $17.40 | 2024 | Subvenite |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $15.38 | 2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $15.12 | 2024 | Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $14.40 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Retta Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.